Back to company

Nectar RHS Komplementar ApS: Financial statements 2022

CVR: 41934530

Nectar RHS Komplementar ApS (CVR 41934530) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -12,500 and a net result of DKK 9,585 compared with DKK 15,600 the year before. Equity amounted to DKK 65,185. The solvency ratio was 84.1%.

Gross Profit
-12,500 kr.
Profit/Loss
9,585 kr.
Equity
65,185 kr.
Total Assets
77,500 kr.
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022--13 t.10 t.65 t.0
2021--5 t.16 t.56 t.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Nectar RHS Komplementar ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Nectar RHS Komplementar ApS: The 2021 annual report is outJul 1, 2022

Nectar RHS Komplementar ApS has published its annual report for 2021. Gross profit came to DKK -5,000, and the net result was DKK 15,600.

About Nectar RHS Komplementar ApS

Nectar RHS Komplementar ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Bjørk Krogshave. The company is owned by PharmaService I/S and Nectar Invest A/S. In 2025, the company reported a gross profit of DKK -5,000 and a net result of DKK 38,849 compared with DKK 58,075 the year before. Equity amounted to DKK 177,416.

Other financial years